Veltuzumab
- Generic Name
- Veltuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 728917-18-8
- Unique Ingredient Identifier
- BPD4DGQ314
- Background
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
- Indication
Investigated for use/treatment in lymphoma (non-hodgkin's).
- Associated Conditions
- -
- Associated Therapies
- -
VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 300
- Registration Number
- NCT01390545
- Locations
- ๐ฌ๐ง
Nycomed Investigational Site, Barnsley, S. Yorkshire, United Kingdom
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01101581
- Locations
- ๐บ๐ธ
Helen F. Graham Cancer Center, Newark, Delaware, United States
๐บ๐ธMDACC Orlando, Orlando, Florida, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 39
- Registration Number
- NCT00596804
- Locations
- ๐ฌ๐ง
University of Leicester, Leicester, United Kingdom
๐ซ๐ทCentre hospitalier Lyon, Lyon, Pierre Benite Cedex, France
๐ซ๐ทService Des Maladies Du Sang, Lille, Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath